Black Diamond Therapeutics, Inc. - Common Stock (NQ:BDTX)

2.085 -0.015 (-0.71%)

Streaming Delayed Price Updated: 10:05 AM EDT, Aug 13, 2026 Add to My Watchlist

Price and Volume

Volume	33,772
Open	2.120
Bid (Size)	2.080 (800)
Ask (Size)	2.090 (900)
Prev. Close	2.100
Today's Range	2.060 - 2.120
52wk Range	1.600 - 4.940
Shares Outstanding	36,213,654
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 05, 2026

From Black Diamond Therapeutics, Inc

Via GlobeNewswire

Black Diamond Therapeutics Touts Silevertinib Lung Cancer Data, Eyes FDA Path ↗

June 06, 2026

Black Diamond Therapeutics (NASDAQ:BDTX) is positioning its lead oncology drug candidate, silevertinib, as a potential treatment for non-small cell lung cancer patients with non-classical EGFR...

Via MarketBeat

Performance

YTD	-16.3%	-16.3%
1 Month	+9.7%	+9.7%
3 Month	-27.1%	-27.1%
6 Month	-6.1%	-6.1%
1 Year	-17.9%	-17.9%

More News

What's Going On With Black Diamond Therapeutics Stock Tuesday? ↗

May 26, 2026

Via Benzinga

Which stocks are experiencing notable movement on Friday? ↗

May 22, 2026

Via Chartmill

Keep an eye on the top gainers and losers in Friday's session. ↗

May 22, 2026

Via Chartmill

Friday's session: gap up and gap down stocks ↗

May 22, 2026

Via Chartmill

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

May 22, 2026

From Black Diamond Therapeutics, Inc

Via GlobeNewswire

Black Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 Study ↗

May 21, 2026

Via MarketBeat

Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations

May 21, 2026

From Black Diamond Therapeutics, Inc

Via GlobeNewswire

Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC

May 19, 2026

From Black Diamond Therapeutics, Inc

Via GlobeNewswire

Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 07, 2026

From Black Diamond Therapeutics, Inc

Via GlobeNewswire

Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting

April 21, 2026

From Black Diamond Therapeutics, Inc

Via GlobeNewswire

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

March 16, 2026

From Black Diamond Therapeutics, Inc

Via GlobeNewswire

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

March 02, 2026

From Black Diamond Therapeutics, Inc

Via GlobeNewswire

Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM

December 03, 2025

From Black Diamond Therapeutics, Inc

Via GlobeNewswire

Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update

December 02, 2025

From Black Diamond Therapeutics, Inc

Via GlobeNewswire

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

November 06, 2025

From Black Diamond Therapeutics, Inc

Via GlobeNewswire

Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 06, 2025

From Black Diamond Therapeutics, Inc

Via GlobeNewswire

4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals ↗

October 10, 2025

Via Benzinga

Black Diamond (BDTX) Q2 Loss Narrows 47% ↗

August 07, 2025

Via The Motley Fool

Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 07, 2025

From Black Diamond Therapeutics, Inc

Via GlobeNewswire

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

May 29, 2025

From Black Diamond Therapeutics, Inc

Via GlobeNewswire

Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 12, 2025

From Black Diamond Therapeutics, Inc

Via GlobeNewswire

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

March 31, 2025

From Black Diamond Therapeutics, Inc

Via GlobeNewswire

These stocks have an unusual volume in today's session ↗

March 21, 2025

Via Chartmill

Frequently Asked Questions

Is Black Diamond Therapeutics, Inc. - Common Stock publicly traded?

Yes, Black Diamond Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Black Diamond Therapeutics, Inc. - Common Stock trade on?

Black Diamond Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Black Diamond Therapeutics, Inc. - Common Stock?

The ticker symbol for Black Diamond Therapeutics, Inc. - Common Stock is BDTX on the Nasdaq Stock Market

What is the current price of Black Diamond Therapeutics, Inc. - Common Stock?

The current price of Black Diamond Therapeutics, Inc. - Common Stock is 2.085

When was Black Diamond Therapeutics, Inc. - Common Stock last traded?

The last trade of Black Diamond Therapeutics, Inc. - Common Stock was at 08/13/26 10:05 AM ET

What is the market capitalization of Black Diamond Therapeutics, Inc. - Common Stock?

The market capitalization of Black Diamond Therapeutics, Inc. - Common Stock is 75.51M

How many shares of Black Diamond Therapeutics, Inc. - Common Stock are outstanding?

Black Diamond Therapeutics, Inc. - Common Stock has 76M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.